[1] 吴菲,林国帧,张晋昕.我国恶性肿瘤发病现状及趋势[J].中国肿瘤,2012,21(2):81.
[2] HURWITZ HI,FEHRENBACHER L,HAINSORTH JD,et al.Bevacizumab in combination with fluorouracil and leucovorin:an active regimen for first-line metastatic colorectal cancer[J].J Clin Oncol,2005,23(15):3502.
[3] GIANTONIO BJ,CATALANO PJ,MEROPOL NJ,et al.Bevacizumab in combination with oxaliplatin,fluorouracil,and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer:results from the Eastern Cooperative Oncology Group Study E3200[J].J Clin Oncol,2007,25(12):1539.
[4] HONG YS,KIM HJ,PARK SJ,et al.Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS[J].Cancer Sci,2013,104(4):473.
[5] SOBRERO AF,MAUREL J,FEHRENBACHER L,et al.EPIC:phase Ⅲ trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer[J].J Clin Oncol,2008,26(14):2311.
[6] PEETERS M,PRICE TJ,CERVANTRS A,et al.Randomized phase Ⅲ study of panitumumab with fluorouracil,leucovorin,and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer[J].J Clin Oncol,2010,28(31):4706.
[7] WALDMAN BC,WANG Y,KILARU K,et al.Induction of intrachromosomal homologous recombination in human cells by raltitrexed,an inhibitor of thymidylate synthase[J].DNA Repair,2008,7(10):1624.
[8] WILSON KS,MALFAIR TAYLOR SC.Raltitrexed:optimism and reality[J].Expert Opin Drug MetabToxicol,2009,5(11):1447.
[9] MAUGHAN TS,JAMES RD,KERR DJ,et al.Comparison of survival,palliation,and quality of life with three chemotherapy regimens in metastatic colorectal cancer:a multicentre randomised trial[J].Lancet,2002,359(9317):1555.
[10] ASCHELE C,BALDO C,SOBRERO AF,et al.Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro[J].Clin Cancer Res,1998,4(5):1323.
[11] CHIARA S,NOBILE MT,TOMASELLO L,et al.Phase Ⅱ trial of irinotecan and raltitrexed in chemotherapy-naive advanced colorectal cancer[J].Anticancer Res,2005,25(2B):1391.
[12] FELIU J,CASTANON C,SALUD A,et al.Phase Ⅱ randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer[J].Br J Cancer,2005,93(11):1230.
[13] 谢达成,李宁,王静珏,等.雷替曲塞联合伊立替康2周方案对比FOLFIRI方案二线治疗晚期结直肠癌的疗效观察[J].临床肿瘤学杂志,2013,18(2):140.
[14] GALLAGHER DJ,KEMENY N.Metastatic colorectal cancer:from improved survival to potential cure[J].Oncology,2010,78(3/4):237.
[15] 周建红,李桂生,李高峰,等.伊立替康联合雷替曲塞在晚期结直肠癌二线化疗中的疗效及安全性研究[J].中国全科医学,2013,16(2B):555.